4Haider S, Ahmad N, Anaissie E, et al.Future directions in the clinical management of amyloid light-chain amyloidosis. Leuk Lymphoma, 2014,55(10) :2241-2251.
5Merlini G, Bellotti V.Molecular mechanisms of amyloidosis. N Engl J Med,2003,349(6) :583-596.
6Gertz MA. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Am J Hematol, 2014, 89 (12) : 1132-1140.
7Chee CE,Lacy MQ,Dogan A,et al.Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk, 2010,10 ( 3 ) : 177-180.
8van Gameren II, Hazenberg BP, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum, 2006, 54(6) :2015-2021.
9Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain anayloidosis : a status report Leuk Lymphoma,2010,51(12) :2181-2187.
10Gertz MA, Li CY, Shirahama T, et al. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis ( immunoglobulin light chain). Arch Intern Med, 1998,148(4) :929-933.
